Third Rock Ventures, RTW Investments and Perceptive Xontogeny led a $200m Series A round in CARGO Therapeutics, a biotechnology company, with participation from Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, and T. Rowe Price Associates. "Our recent accomplishments and this new funding enable us to build a truly differentiated platform that is poised to meaningfully advance the cell therapy field. We are extremely pleased to have the support of seasoned new and current investors who share our vision of developing the next generation of best-in-class CARs that have the potential to extend life for many more patients," Gina Chapman,CARGO Therapeutics CEO.